2017 Conference Publication First Australian registry of patients with wild type cardiac amyloidosis (ATTRwt): Queensland experienceBurrage, M., Korczyk, D. and Mollee, P. (2017). First Australian registry of patients with wild type cardiac amyloidosis (ATTRwt): Queensland experience. ESC Congress 2017, Barcelona, Spain, 26-30 August 2017. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/eurheartj/ehx502.1955 |
2017 Journal Article Monitoring of light chain myeloma - time for a changeMollee, Peter and Tate, Jill (2017). Monitoring of light chain myeloma - time for a change. British Journal of Haematology, 178 (2), 177-178. doi: 10.1111/bjh.14752 |
2017 Journal Article Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trialRickard, Claire M., Marsh, Nicole M., Webster, Joan, Gavin, Nicole C., Chan, Raymond J., McCarthy, Alexandra L., Mollee, Peter, Ullman, Amanda J., Kleidon, Tricia, Chopra, Vineet, Zhang, Li, McGrail, Matthew R., Larsen, Emily, Abu Choudhury, Md, Keogh, Samantha, Alexandrou, Evan, McMillan, David J., Mervin, Merehau Cindy, Paterson, David L., Cooke, Marie, Ray-Barruel, Gillian, Castillo, Maria Isabel, Hallahan, Andrew, Corley, Amanda and Playford, E. Geoffrey (2017). Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. BMJ Open, 7 (6) e015291, e015291. doi: 10.1136/bmjopen-2016-015291 |
2017 Journal Article Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical settingSharkey, Megan M., McKavanagh, Daniel, Walpole, Euan, Mollee, Peter and Hollingworth, Samantha A. (2017). Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. International Journal of Clinical Pharmacy, 39 (4), 836-843. doi: 10.1007/s11096-017-0480-0 |
2017 Journal Article Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?Hill, Michelle M. and Mollee, Peter N. (2017). Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?. Expert Review of Proteomics, 14 (7), 565-566. doi: 10.1080/14789450.2017.1322905 |
2017 Journal Article Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemiaFleming, Shaun, Ong, Doen Ming, Jackson, Kathryn, Avery, Sharon, Mollee, Peter, Marlton, Paula, Kennedy, Glen and Wei, Andrew H (2017). Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. British Journal of Haematology, 177 (2), 328-330. doi: 10.1111/bjh.14063 |
2017 Journal Article Malabsorption secondary to gout-induced amyloidosisAzzam, Ali, Balasubramaniam, Renuka, Safa, Shahram, McIvor, Carolyn and Mollee, Peter (2017). Malabsorption secondary to gout-induced amyloidosis. ACG Case Reports Journal, 4 (1), e32. doi: 10.14309/crj.2017.32 |
2017 Journal Article Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trialTrappe, Ralf U., Dierickx, Daan, Zimmermann, Heiner, Morschhauser, Franck, Mollee, Peter, Zaucha, Jan M., Dreyling, Martin H., Duhrsen, Ulrich, Reinke, Petra, Verhoef, Gregor, Subklewe, Marion, Huttmann, Andreas, Tousseyn, Thomas, Salles, Gilles, Kliem, Volker, Hauser, Ingeborg A., Tarella, Corrado, Neste, Eric Van Den, Gheysens, Olivier, Anagnostopoulos, Ioannis, Leblond, Veronique, Riess, Hanno and Choquet, Sylvain (2017). Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial. Journal of Clinical Oncology, 35 (5), 536-543. doi: 10.1200/JCO.2016.69.3564 |
2017 Journal Article Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome : MGRS triggering aHUSMahmood, Usman, Isbel, Nicole, Mollee, Peter, Mallett, Andrew, Govindarajulu, Sridevi and Francis, Ross (2017). Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome : MGRS triggering aHUS. Nephrology, 22 (S1), 15-17. doi: 10.1111/nep.12934 |
2017 Conference Publication Combination bone marrow imaging using PET-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosisTate, Courtney, Miles, Kenneth and Mollee, Peter (2017). Combination bone marrow imaging using PET-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis. 16th International Myeloma Workshop, New Delhi, India, 1-4 March 2017. Elsevier BV. doi: 10.1016/j.clml.2017.03.081 |
2017 Conference Publication Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot studyLaw, W. Phillip, Wang, William, Moore, Peter, Mollee, Peter and Ng, Arnold (2017). Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study. XVth International Symposium on Amyloidosis, Indianapolis, IN, USA, 2014. Abingdon, Oxfordshire, United Kingdom: Taylor & Francis. doi: 10.1080/13506129.2017.1281120 |
2017 Journal Article Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupTalaulikar, Dipti, Tam, Constantine S., Joshua, Douglas, Ho, Joy Phoebe, Szer, Jeff, Quach, Hang, Spencer, Andrew, Harrison, Simon, Mollee, Peter, Roberts, Andrew W., Horvath, Noemi, Lee, Cindy, Zannettino, Andrew, Brown, Ross, Augustson, Bradley, Jaksic, Wilfrid, Gibson, John, Kalff, Anna, Johnston, Anna, Trotman, Judith, Kalro, Akash, Grigoriadis, George, Ward, Chris and Prince, H. Miles (2017). Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 47 (1), 35-49. doi: 10.1111/imj.13311 |
2017 Conference Publication Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled TrialMollee, Peter, Okano, Satomi, Looke, David, Kennedy, Glen, Harper, John, Clouston, John, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa and Jones, Mark (2017). Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled Trial. In: 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, (). 9-12 December 2017. |
2017 Conference Publication The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic LeukaemiaTobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. |
2017 Conference Publication Evaluation of bortezomib use in Queensland public hospitals for the treatment of multiple myelomaWalpole, Euan, Mollee, Peter, McPherson, Ian, Loke, Crystal and Hollingworth, Samantha (2017). Evaluation of bortezomib use in Queensland public hospitals for the treatment of multiple myeloma. COSA's 44th Annual Scientific Meeting, Sydney, NSW, Australia, 13-15 November 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12799 |
2016 Journal Article Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registryBergin, Krystal, Moore, Elizabeth, McQuilten, Zoe, Wood, Erica, Augustson, Bradley, Blacklock, Hilary, Ho, Joy, Horvath, Noemi, King, Tracy, McNeil, John, Mollee, Peter, Quach, Hang, Reid, Christopher M., Rosengarten, Brian, Walker, Patricia and Spencer, Andrew (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. Bmc Medical Research Methodology, 16 (1) 151, 151. doi: 10.1186/s12874-016-0250-z |
2016 Journal Article The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experienceMoore, Peter T., Burrage, Matthew K., Mackenzie, Emily, Law, W. Philip, Korczyk, Dariusz and Mollee, Peter (2016). The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience. Heart, Lung and Circulation, 26 (11), 1183-1190. doi: 10.1016/j.hlc.2016.12.017 |
2016 Journal Article Cardiac amyloid imaging with 18F-florbetaben PET: a pilot studyLaw, W. Phillip, Wang, William Y. S., Moore, Peter T., Mollee, Peter N. and Ng, Arnold C. T. (2016). Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. Journal of Nuclear Medicine, 57 (11), 1733-1739. doi: 10.2967/jnumed.115.169870 |
2016 Journal Article Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometryMollee, Peter, Boros, Samuel, Loo, Dorothy, Ruelcke, Jayde E., Lakis, Vanessa A., Cao, Kim‑Anh Lê, Renaut, Patricia and Hill, Michelle M. (2016). Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clinical Proteomics, 13 (1) 30, 1-6. doi: 10.1186/s12014-016-9133-x |
2016 Journal Article Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patientsBurgess, M., Mapp, S., Mazzieri, R., Cheung, C., Cahmbers, L., Mattarollo, S., Mollee, P., Gill, D. and Saunders, N. A. (2016). Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients. Oncogene, 36 (17), 2366-2376. doi: 10.1038/onc.2016.387 |